Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Breast Cancer Liquid Biopsy Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for liquid biopsy in breast cancer has experienced swift growth in recent years. Its worth, expected to rise from $0.78 billion in 2024 to $0.89 billion in 2025, signifies a compound annual growth rate (CAGR) of 14.2%. This sharp growth in the historic period is due to breakthroughs in next-generation sequencing (ngs), a higher incidence rate of breast cancer, an escalating demand for non-surgical diagnosis methods, a rising trend towards personalized medicine, and an increase in financial support for cancer research.

In the coming years, the breast cancer liquid biopsy market is anticipated to experience significant expansion, reaching $1.53 billion by 2029 at an annual compounded growth rate (CAGR) of 14.5%. This projected growth over the forecast period can be linked to several factors, such as advancements in liquid biopsy assays technology, increased use of liquid biopsy for early-stage cancer screenings, heightened demand for real-time cancer tracking, increased use in precision oncology, and escalating investments in research and development in the liquid biopsy field. During the forecast period, the market landscape will be shaped by emerging trends, including the use of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing technology, growth of multi-omics liquid biopsy platforms, enhancements in sensitivity and specificity of liquid biopsy, and the adoption of digital PCR for highly precise mutation detection.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are the Core Market Drivers Propelling Growth in the Breast Cancer Liquid Biopsy Industry?

The upsurge in incidents of breast cancer is predicted to spur the expansion of the breast cancer liquid biopsy market. Breast cancer, a cancer variant that originates in the breast cells, particularly in the lobules (the milk-producing glands) or ducts (channels conveying milk to the nipple), is on an upward trajectory. This is attributed to factors like genetic factors, hormonal imbalances, an aging population, alterations in lifestyle, obesity, alcohol intake, insufficient physical exertion, exposure to radiation, and environmental toxins. A breast cancer liquid biopsy plays a critical role in treatment by identifying circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, thus facilitating real-time disease monitoring. It is beneficial for gauging treatment response, recognizing resistance to therapy, and uncovering genetic alterations for specific therapies. For instance, the American Cancer Society, a US-based nonprofit organization committed to cancer research, education, advocacy, and patient support, anticipates the number of new breast cancer cases to escalate to 319,750 in 2025 from 313,510 cases in 2024. Consequently, the escalating breast cancer cases are encouraging the expansion of the breast cancer liquid biopsy market.

How Is the Breast Cancer Liquid Biopsy Market Segmented?

The breast cancer liquid biopsymarket covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Which Regions Are Driving the Next Phase of the Breast Cancer Liquid Biopsy Market Growth?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Breast Cancer Liquid Biopsy Industry?

Leading firms in the breast cancer liquid biopsy market are concentrating on the creation of novel products, including companion diagnostics, to facilitate personalized treatment strategies by pinpointing patients who stand to gain from specific treatments. The function of companion diagnostics is to use liquid biopsy technologies to identify biomarkers such as genetic changes, circulating tumor DNA (ctDNA), or protein expressions that signal responsiveness to treatment. For instance, Guardant Health Inc., a biotechnology company located in the US, was given approval by the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant), which is a treatment for advanced or metastatic breast cancer patients with ESR1 mutations in January 2023. This approval empowers oncologists to apply the test for comprehensive genomic profiling to spot patients who could potentially benefit from this targeted therapy. It is the first time the U.S. Food and Drug Administration (FDA) has approved a Guardant Health product for breast cancer, broadening its contributions to precision oncology.

View the full report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

How Is the Breast Cancer Liquid Biopsy Market Defined and What Are Its Core Parameters?

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient’s blood or other bodily fluids. It provides valuable insights into the presence, progression, and genetic profile of breast cancer without requiring a traditional tissue biopsy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model